Clinical Trial Update: Epanova® for Lowering Very High Triglycerides II (EVOLVE II) [Phase 3]

View source ↗

Summary

Phase 3 trial EVOLVE II evaluating Epanova for lowering very high triglycerides has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• Epanova (icosapent ethyl)

Snippet

Sponsor: AstraZeneca | Conditions: Hypertriglyceridemia | Phase 3 | Status: COMPLETED | Results posted: 2016-01-15